Dr. Richard Hurwitz is a Co-Director of the Retinoblastoma Program. Dr. Richard Hurwitz studies the potential use of gene therapy for the treatment of ocular diseases. He has shown that a novel treatment for retinoblastoma using suicide gene therapy is safe and possibly effective in children. To further refine this therapeutic option, Dr. Hurwitz is studying the cellular origin of retinoblastoma and the differences between invasive and non-invasive forms of this disease.
In addition, in vivo models of retinitis pigmentosa and macular degeneration are being used to develop gene therapy treatments for retinal degenerative diseases. The mechanism of adenoviral-mediated transgene expression in the ocular environment is being explored with goals of providing future molecular targets to modulate adenoviral-mediated gene therapy for both retinoblastoma and retinal degenerative diseases and possibly of controlling adenovirus infection in general.
Gene therapy for ocular diseases
Cellular origin of retinoblastoma
Retinal degenerative diseases
American Board of Pediatrics
American Board of Pediatrics-Hematology/Oncology